康寧傑瑞製藥(09966.HK)與賽諾菲就治療乳腺癌展開戰略合作
康寧傑瑞製藥(09966.HK)公布,於6月9日旗下全資附屬公司江蘇康寧傑瑞與賽諾菲訂立獨家選擇權協議以進行戰略合作,通過聯合賽諾菲用於人表皮生長因子受體2(HER2)呈陽性的乳腺癌患者的產品泰索帝,以推進KN026(一種抗HER2的基於Fc的雙特異性單克隆抗體)的臨床研究。
根據該協議,江蘇康寧傑瑞負責正在進行中的KN026臨床試驗以及KN026和泰索帝的新聯合研究。賽諾菲負責向江蘇康寧傑瑞提供一定數量的泰索帝,以進行預期的聯合研究。江蘇康寧傑瑞有權享有任何及所有研發計劃的所有權利、法定權及權益。
公司認為,通過與全球領先的生物製藥公司賽諾菲合作,集團將進一步推動KN026在中國及全球的發展戰略,加速為數百萬名患者的生活提供實質性的改善,並在將來擴展至探討其他HER2陽性實體腫瘤的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.